Review



elisa buffer  (Chondrex Inc)


Bioz Verified Symbol Chondrex Inc is a verified supplier
Bioz Manufacturer Symbol Chondrex Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Chondrex Inc elisa buffer
    Elisa Buffer, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 110 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/pmc13098406-51-32-34
    Average 96 stars, based on 110 article reviews
    elisa buffer - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Microarray:

    Article Title: System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
    Article Snippet: .. For probing, microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface then incubated for 2h with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24- chamber hybridization cassette (The Gel Company) and incubated with plasma from SARS CoV2 qPCR confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
    Article Snippet: .. Microarray slides were briefly rinsed twice with Tris-buffered saline containing Tween 20 (TBST: 0.1 M Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST, then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from NAT-confirmed SARS-CoV-2–positive and –negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
    Article Snippet: .. Microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from SARS CoV-2 NAT confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Saline:

    Article Title: System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
    Article Snippet: .. For probing, microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface then incubated for 2h with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24- chamber hybridization cassette (The Gel Company) and incubated with plasma from SARS CoV2 qPCR confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
    Article Snippet: .. Microarray slides were briefly rinsed twice with Tris-buffered saline containing Tween 20 (TBST: 0.1 M Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST, then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from NAT-confirmed SARS-CoV-2–positive and –negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
    Article Snippet: .. Microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from SARS CoV-2 NAT confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Incubation:

    Article Title: System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
    Article Snippet: .. For probing, microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface then incubated for 2h with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24- chamber hybridization cassette (The Gel Company) and incubated with plasma from SARS CoV2 qPCR confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
    Article Snippet: .. Microarray slides were briefly rinsed twice with Tris-buffered saline containing Tween 20 (TBST: 0.1 M Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST, then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from NAT-confirmed SARS-CoV-2–positive and –negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
    Article Snippet: .. Microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from SARS CoV-2 NAT confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Enzyme-linked Immunosorbent Assay:

    Article Title: System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
    Article Snippet: .. For probing, microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface then incubated for 2h with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24- chamber hybridization cassette (The Gel Company) and incubated with plasma from SARS CoV2 qPCR confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
    Article Snippet: .. Microarray slides were briefly rinsed twice with Tris-buffered saline containing Tween 20 (TBST: 0.1 M Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST, then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from NAT-confirmed SARS-CoV-2–positive and –negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
    Article Snippet: .. Microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from SARS CoV-2 NAT confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Blocking Assay:

    Article Title: System-wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep proteome and phosphoproteome analysis
    Article Snippet: .. For probing, microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface then incubated for 2h with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24- chamber hybridization cassette (The Gel Company) and incubated with plasma from SARS CoV2 qPCR confirmed positive and negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
    Article Snippet: .. Microarray slides were briefly rinsed twice with Tris-buffered saline containing Tween 20 (TBST: 0.1 M Tris-HCl at pH 7.4, 150 mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST, then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from NAT-confirmed SARS-CoV-2–positive and –negative patients (1:250 dilution in ChonBlock).

    Article Title: Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
    Article Snippet: .. Microarray slides were briefly rinsed twice with TBST (Tris buffered saline containing Tween 20: 0.1M Tris-HCl, pH 7.4, 150mM NaCl, and 0.1% Tween 20) to wet the surface and then incubated for 2 hours with ChonBlock ELISA blocking and antibody dilution buffer (Chondrex Inc). .. Slides were briefly rinsed with TBST then inserted into an ArraySlide 24-chamber hybridization cassette (The Gel Company) for the proteome array or ProPlate Multi-Well Chamber (Grace Bio-Labs) for the peptide arrays and incubated with plasma from SARS CoV-2 NAT confirmed positive and negative patients (1:250 dilution in ChonBlock).



    Similar Products

    elisa buffer  (Chondrex Inc)
    96
    Chondrex Inc elisa buffer
    Elisa Buffer, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/pmc13098406-51-32-34
    Average 96 stars, based on 1 article reviews
    elisa buffer - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    chonblock blocking solution  (Chondrex Inc)
    96
    Chondrex Inc chonblock blocking solution
    Chonblock Blocking Solution, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/pm42001719-71-9-13
    Average 96 stars, based on 1 article reviews
    chonblock blocking solution - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    chonblock blocking sample  (Chondrex Inc)
    96
    Chondrex Inc chonblock blocking sample
    Chonblock Blocking Sample, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/bio_rxiv__64898__2026__03__16__711963-214-24-29
    Average 96 stars, based on 1 article reviews
    chonblock blocking sample - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    chonblock elisa buffer  (Chondrex Inc)
    96
    Chondrex Inc chonblock elisa buffer
    a, Immunization and sampling scheme. Female C57BL/6J mice (8–10 weeks old; n = 5 per group) were immunized intramuscularly with 10 μg of ARCA-capped nucleocapsid (NP) mRNA–LNP on days 0 and 14 using three UTR configurations (CCHFV-UTR–NP, T-UTR–NP, or ACTA-1–UTR–NP). Negative-control animals received 1× PBS intramuscularly. On day 28, animals were euthanized and blood and spleens were collected for serology <t>(ELISA)</t> and cellular immunogenicity assays (ELISPOT and intracellular cytokine staining). b, Antigen-specific cytokine secretion by ELISPOT. Splenocytes harvested on day 28 were stimulated for 24 h with recombinant CCHFV NP (10 μg ml⁻¹) and analyzed for IFN-γ and IL-2 spot-forming cells (SFCs; normalized per 1.5 × 10⁶ input cells). Representative ELISPOT wells are shown adjacent to quantification. All NP mRNA–LNP vaccines induced significantly higher IL-2 secretion than stimulated negative controls. Constructs containing CCHFV and ACTA-1 UTRs elicited significantly greater IL-2 responses than the T-UTR construct and negative controls, whereas IFN-γ responses were also significantly increased relative to controls, with UTR-dependent differences indicated by the displayed P values. c, CD8⁺ T cell cytokine production. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by intracellular cytokine staining (ICS) to quantify frequencies of IFN-γ⁺, IL-2⁺, and TNF-α⁺ CD8⁺ T cells. The T-UTR construct increased CD8⁺ IFN-γ, IL-2, and TNF-α relative to negative controls, although the three vaccine candidates did not differ significantly from one another across these CD8⁺ readouts (as indicated by the annotated P values). d, CD4⁺ T cell cytokine polarization. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by ICS to quantify IFN-γ⁺, IL-2⁺, IL-4⁺, TNF-α⁺, and IL-17A⁺ CD4⁺ T cells. The ACTA-1–UTR construct induced markedly higher frequencies of all five cytokines compared with the CCHFV-UTR and T-UTR constructs and the negative-control group, indicating broadened helper polarization. CCHFV-UTR– and T-UTR–based constructs produced comparable but lower cytokine frequencies in CD4⁺ T cells. Bars represent group means with individual animals overlaid as points; error bars denote variability within groups. Statistical analyses were performed in GraphPad. Between-group comparisons used one-way ANOVA with Tukey’s multiple comparisons test; when normality assumptions were not met, the Kruskal–Wallis test was used. A significance threshold of P < 0.05 was applied unless otherwise indicated, and exact P values are shown in the figure.
    Chonblock Elisa Buffer, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/bio_rxiv__64898__2026__01__17__699915-211-14-17
    Average 96 stars, based on 1 article reviews
    chonblock elisa buffer - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    chonblock  (Chondrex Inc)
    96
    Chondrex Inc chonblock
    a, Immunization and sampling scheme. Female C57BL/6J mice (8–10 weeks old; n = 5 per group) were immunized intramuscularly with 10 μg of ARCA-capped nucleocapsid (NP) mRNA–LNP on days 0 and 14 using three UTR configurations (CCHFV-UTR–NP, T-UTR–NP, or ACTA-1–UTR–NP). Negative-control animals received 1× PBS intramuscularly. On day 28, animals were euthanized and blood and spleens were collected for serology <t>(ELISA)</t> and cellular immunogenicity assays (ELISPOT and intracellular cytokine staining). b, Antigen-specific cytokine secretion by ELISPOT. Splenocytes harvested on day 28 were stimulated for 24 h with recombinant CCHFV NP (10 μg ml⁻¹) and analyzed for IFN-γ and IL-2 spot-forming cells (SFCs; normalized per 1.5 × 10⁶ input cells). Representative ELISPOT wells are shown adjacent to quantification. All NP mRNA–LNP vaccines induced significantly higher IL-2 secretion than stimulated negative controls. Constructs containing CCHFV and ACTA-1 UTRs elicited significantly greater IL-2 responses than the T-UTR construct and negative controls, whereas IFN-γ responses were also significantly increased relative to controls, with UTR-dependent differences indicated by the displayed P values. c, CD8⁺ T cell cytokine production. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by intracellular cytokine staining (ICS) to quantify frequencies of IFN-γ⁺, IL-2⁺, and TNF-α⁺ CD8⁺ T cells. The T-UTR construct increased CD8⁺ IFN-γ, IL-2, and TNF-α relative to negative controls, although the three vaccine candidates did not differ significantly from one another across these CD8⁺ readouts (as indicated by the annotated P values). d, CD4⁺ T cell cytokine polarization. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by ICS to quantify IFN-γ⁺, IL-2⁺, IL-4⁺, TNF-α⁺, and IL-17A⁺ CD4⁺ T cells. The ACTA-1–UTR construct induced markedly higher frequencies of all five cytokines compared with the CCHFV-UTR and T-UTR constructs and the negative-control group, indicating broadened helper polarization. CCHFV-UTR– and T-UTR–based constructs produced comparable but lower cytokine frequencies in CD4⁺ T cells. Bars represent group means with individual animals overlaid as points; error bars denote variability within groups. Statistical analyses were performed in GraphPad. Between-group comparisons used one-way ANOVA with Tukey’s multiple comparisons test; when normality assumptions were not met, the Kruskal–Wallis test was used. A significance threshold of P < 0.05 was applied unless otherwise indicated, and exact P values are shown in the figure.
    Chonblock, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/pmc12775405-353-15-16
    Average 96 stars, based on 1 article reviews
    chonblock - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    chonblock blocking  (Chondrex Inc)
    96
    Chondrex Inc chonblock blocking
    a, Immunization and sampling scheme. Female C57BL/6J mice (8–10 weeks old; n = 5 per group) were immunized intramuscularly with 10 μg of ARCA-capped nucleocapsid (NP) mRNA–LNP on days 0 and 14 using three UTR configurations (CCHFV-UTR–NP, T-UTR–NP, or ACTA-1–UTR–NP). Negative-control animals received 1× PBS intramuscularly. On day 28, animals were euthanized and blood and spleens were collected for serology <t>(ELISA)</t> and cellular immunogenicity assays (ELISPOT and intracellular cytokine staining). b, Antigen-specific cytokine secretion by ELISPOT. Splenocytes harvested on day 28 were stimulated for 24 h with recombinant CCHFV NP (10 μg ml⁻¹) and analyzed for IFN-γ and IL-2 spot-forming cells (SFCs; normalized per 1.5 × 10⁶ input cells). Representative ELISPOT wells are shown adjacent to quantification. All NP mRNA–LNP vaccines induced significantly higher IL-2 secretion than stimulated negative controls. Constructs containing CCHFV and ACTA-1 UTRs elicited significantly greater IL-2 responses than the T-UTR construct and negative controls, whereas IFN-γ responses were also significantly increased relative to controls, with UTR-dependent differences indicated by the displayed P values. c, CD8⁺ T cell cytokine production. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by intracellular cytokine staining (ICS) to quantify frequencies of IFN-γ⁺, IL-2⁺, and TNF-α⁺ CD8⁺ T cells. The T-UTR construct increased CD8⁺ IFN-γ, IL-2, and TNF-α relative to negative controls, although the three vaccine candidates did not differ significantly from one another across these CD8⁺ readouts (as indicated by the annotated P values). d, CD4⁺ T cell cytokine polarization. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by ICS to quantify IFN-γ⁺, IL-2⁺, IL-4⁺, TNF-α⁺, and IL-17A⁺ CD4⁺ T cells. The ACTA-1–UTR construct induced markedly higher frequencies of all five cytokines compared with the CCHFV-UTR and T-UTR constructs and the negative-control group, indicating broadened helper polarization. CCHFV-UTR– and T-UTR–based constructs produced comparable but lower cytokine frequencies in CD4⁺ T cells. Bars represent group means with individual animals overlaid as points; error bars denote variability within groups. Statistical analyses were performed in GraphPad. Between-group comparisons used one-way ANOVA with Tukey’s multiple comparisons test; when normality assumptions were not met, the Kruskal–Wallis test was used. A significance threshold of P < 0.05 was applied unless otherwise indicated, and exact P values are shown in the figure.
    Chonblock Blocking, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/chonblock+elisa+blocking/ChonBlock+Blocking%2FSample+Dilution+ELISA+Buffer/pmc12658140-230-9-14
    Average 96 stars, based on 1 article reviews
    chonblock blocking - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    a, Immunization and sampling scheme. Female C57BL/6J mice (8–10 weeks old; n = 5 per group) were immunized intramuscularly with 10 μg of ARCA-capped nucleocapsid (NP) mRNA–LNP on days 0 and 14 using three UTR configurations (CCHFV-UTR–NP, T-UTR–NP, or ACTA-1–UTR–NP). Negative-control animals received 1× PBS intramuscularly. On day 28, animals were euthanized and blood and spleens were collected for serology (ELISA) and cellular immunogenicity assays (ELISPOT and intracellular cytokine staining). b, Antigen-specific cytokine secretion by ELISPOT. Splenocytes harvested on day 28 were stimulated for 24 h with recombinant CCHFV NP (10 μg ml⁻¹) and analyzed for IFN-γ and IL-2 spot-forming cells (SFCs; normalized per 1.5 × 10⁶ input cells). Representative ELISPOT wells are shown adjacent to quantification. All NP mRNA–LNP vaccines induced significantly higher IL-2 secretion than stimulated negative controls. Constructs containing CCHFV and ACTA-1 UTRs elicited significantly greater IL-2 responses than the T-UTR construct and negative controls, whereas IFN-γ responses were also significantly increased relative to controls, with UTR-dependent differences indicated by the displayed P values. c, CD8⁺ T cell cytokine production. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by intracellular cytokine staining (ICS) to quantify frequencies of IFN-γ⁺, IL-2⁺, and TNF-α⁺ CD8⁺ T cells. The T-UTR construct increased CD8⁺ IFN-γ, IL-2, and TNF-α relative to negative controls, although the three vaccine candidates did not differ significantly from one another across these CD8⁺ readouts (as indicated by the annotated P values). d, CD4⁺ T cell cytokine polarization. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by ICS to quantify IFN-γ⁺, IL-2⁺, IL-4⁺, TNF-α⁺, and IL-17A⁺ CD4⁺ T cells. The ACTA-1–UTR construct induced markedly higher frequencies of all five cytokines compared with the CCHFV-UTR and T-UTR constructs and the negative-control group, indicating broadened helper polarization. CCHFV-UTR– and T-UTR–based constructs produced comparable but lower cytokine frequencies in CD4⁺ T cells. Bars represent group means with individual animals overlaid as points; error bars denote variability within groups. Statistical analyses were performed in GraphPad. Between-group comparisons used one-way ANOVA with Tukey’s multiple comparisons test; when normality assumptions were not met, the Kruskal–Wallis test was used. A significance threshold of P < 0.05 was applied unless otherwise indicated, and exact P values are shown in the figure.

    Journal: bioRxiv

    Article Title: A modular mRNA–LNP vaccine platform enables integrated RNA, lipid and antigen design to protect against CCHFV

    doi: 10.64898/2026.01.17.699915

    Figure Lengend Snippet: a, Immunization and sampling scheme. Female C57BL/6J mice (8–10 weeks old; n = 5 per group) were immunized intramuscularly with 10 μg of ARCA-capped nucleocapsid (NP) mRNA–LNP on days 0 and 14 using three UTR configurations (CCHFV-UTR–NP, T-UTR–NP, or ACTA-1–UTR–NP). Negative-control animals received 1× PBS intramuscularly. On day 28, animals were euthanized and blood and spleens were collected for serology (ELISA) and cellular immunogenicity assays (ELISPOT and intracellular cytokine staining). b, Antigen-specific cytokine secretion by ELISPOT. Splenocytes harvested on day 28 were stimulated for 24 h with recombinant CCHFV NP (10 μg ml⁻¹) and analyzed for IFN-γ and IL-2 spot-forming cells (SFCs; normalized per 1.5 × 10⁶ input cells). Representative ELISPOT wells are shown adjacent to quantification. All NP mRNA–LNP vaccines induced significantly higher IL-2 secretion than stimulated negative controls. Constructs containing CCHFV and ACTA-1 UTRs elicited significantly greater IL-2 responses than the T-UTR construct and negative controls, whereas IFN-γ responses were also significantly increased relative to controls, with UTR-dependent differences indicated by the displayed P values. c, CD8⁺ T cell cytokine production. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by intracellular cytokine staining (ICS) to quantify frequencies of IFN-γ⁺, IL-2⁺, and TNF-α⁺ CD8⁺ T cells. The T-UTR construct increased CD8⁺ IFN-γ, IL-2, and TNF-α relative to negative controls, although the three vaccine candidates did not differ significantly from one another across these CD8⁺ readouts (as indicated by the annotated P values). d, CD4⁺ T cell cytokine polarization. Day-28 splenocytes were stimulated for 5 h with recombinant NP (10 μg ml⁻¹) and analyzed by ICS to quantify IFN-γ⁺, IL-2⁺, IL-4⁺, TNF-α⁺, and IL-17A⁺ CD4⁺ T cells. The ACTA-1–UTR construct induced markedly higher frequencies of all five cytokines compared with the CCHFV-UTR and T-UTR constructs and the negative-control group, indicating broadened helper polarization. CCHFV-UTR– and T-UTR–based constructs produced comparable but lower cytokine frequencies in CD4⁺ T cells. Bars represent group means with individual animals overlaid as points; error bars denote variability within groups. Statistical analyses were performed in GraphPad. Between-group comparisons used one-way ANOVA with Tukey’s multiple comparisons test; when normality assumptions were not met, the Kruskal–Wallis test was used. A significance threshold of P < 0.05 was applied unless otherwise indicated, and exact P values are shown in the figure.

    Article Snippet: Plates were washed once with 0.1% Tween-20 in PBS and blocked with 200 μL ChonBlock ELISA Buffer (Chondrex, Cat #9068) for 2 hours at room temperature.

    Techniques: Sampling, Negative Control, Enzyme-linked Immunosorbent Assay, Immunopeptidomics, Enzyme-linked Immunospot, Staining, Recombinant, Vaccines, Construct, Produced

    a, The immunization schedule and experimental workflow are shown for AG-capped mRNA–LNP formulations encoding nucleocapsid (NP), mutant nucleocapsid (NPmut), sGCs, and sGCs (GP38Δglyc). Female C57BL/6J mice (8–10 weeks old) were immunized intramuscularly with 10 µg of each mRNA–LNP vaccine on days 0 and 14. Blood, spleens, and inguinal lymph nodes were collected on day 28 for downstream immunological analyses, including ELISA, germinal center (GC) B and T follicular helper (Tfh) cell profiling, and ELISPOT assays. b, Splenocytes were stimulated for 24 hours with 10 µg/mL of recombinant nucleocapsid or GP38 proteins and analyzed by ELISPOT to quantify IFN-γ and IL-4 secretion. The NP and NPmut groups exhibited significantly higher IFN-γ–secreting cell frequencies compared with sGCs, sGCs (GP38Δglyc), and negative control groups, whereas sGCs and sGCs (GP38Δglyc) formulations elicited stronger IL-4 responses than NP, NPmut, and controls. c, GC B and Tfh cell populations were quantified in lymph nodes collected on day 28. The NPmut group displayed a significantly increased percentage of GC B and Tfh cells relative to negative controls, while the NP group showed a higher frequency of GC B cells compared with controls. Antigen-specific GC B cells were elevated across all vaccine groups relative to controls, with no significant differences among vaccine formulations. d, Antibody levels measured by in-house ELISA on day 28 showed that two out of eight mice in the NPmut group had detectable antigen-specific antibodies, while all samples in the sGCs and sGCs (GP38Δglyc) groups exhibited significantly higher antibody titers compared with negative controls. No significant differences were observed between sGCs and sGCs (GP38Δglyc) groups. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test. Significant differences are shown as p -values.

    Journal: bioRxiv

    Article Title: A modular mRNA–LNP vaccine platform enables integrated RNA, lipid and antigen design to protect against CCHFV

    doi: 10.64898/2026.01.17.699915

    Figure Lengend Snippet: a, The immunization schedule and experimental workflow are shown for AG-capped mRNA–LNP formulations encoding nucleocapsid (NP), mutant nucleocapsid (NPmut), sGCs, and sGCs (GP38Δglyc). Female C57BL/6J mice (8–10 weeks old) were immunized intramuscularly with 10 µg of each mRNA–LNP vaccine on days 0 and 14. Blood, spleens, and inguinal lymph nodes were collected on day 28 for downstream immunological analyses, including ELISA, germinal center (GC) B and T follicular helper (Tfh) cell profiling, and ELISPOT assays. b, Splenocytes were stimulated for 24 hours with 10 µg/mL of recombinant nucleocapsid or GP38 proteins and analyzed by ELISPOT to quantify IFN-γ and IL-4 secretion. The NP and NPmut groups exhibited significantly higher IFN-γ–secreting cell frequencies compared with sGCs, sGCs (GP38Δglyc), and negative control groups, whereas sGCs and sGCs (GP38Δglyc) formulations elicited stronger IL-4 responses than NP, NPmut, and controls. c, GC B and Tfh cell populations were quantified in lymph nodes collected on day 28. The NPmut group displayed a significantly increased percentage of GC B and Tfh cells relative to negative controls, while the NP group showed a higher frequency of GC B cells compared with controls. Antigen-specific GC B cells were elevated across all vaccine groups relative to controls, with no significant differences among vaccine formulations. d, Antibody levels measured by in-house ELISA on day 28 showed that two out of eight mice in the NPmut group had detectable antigen-specific antibodies, while all samples in the sGCs and sGCs (GP38Δglyc) groups exhibited significantly higher antibody titers compared with negative controls. No significant differences were observed between sGCs and sGCs (GP38Δglyc) groups. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test. Significant differences are shown as p -values.

    Article Snippet: Plates were washed once with 0.1% Tween-20 in PBS and blocked with 200 μL ChonBlock ELISA Buffer (Chondrex, Cat #9068) for 2 hours at room temperature.

    Techniques: Mutagenesis, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot, Recombinant, Negative Control

    a, Female C57BL/6J mice were immunized intramuscularly with Cleancap M6 mRNA–LNP formulations encoding nucleocapsid (NP), mutant nucleocapsid (NPmut), sGCs, or sGCs (GP38Δglyc). Blood, spleens, and lymph nodes were collected on day 35 for downstream analyses, including ELISA, dendritic cell profiling, and ELISPOT assays. b, Splenocytes were stimulated for 24 hours with 10 µg/mL of nucleocapsid or GP38 proteins and analyzed by ELISPOT for IFN-γ and IL-4 secretion. NP and NPmut groups induced significantly higher IFN-γ responses compared with sGCs, sGCs (GP38Δglyc), and negative control, whereas sGCs and sGCs (GP38Δglyc) showed no significant IFN-γ response. None of the vaccine groups elicited significant IL-4 production. c, Splenocytes were stimulated ex vivo for 24 hours with 10 µg/mL of nucleocapsid or GP38 proteins and analyzed for intracellular cytokines IFN-γ, IL-2, and TNF-α in CD8⁺ and CD4⁺ T cells. All vaccine groups elicited robust CD4⁺ and CD8⁺ T cell responses compared with negative controls, except for sGCs (GP38Δglyc). NP vaccination induced significantly higher cytokine production in CD8⁺ T cells relative to control, whereas sGCs (GP38Δglyc) uniquely enhanced IL-2 and TNF-α in CD4⁺ T cells. No significant differences were observed among vaccine groups. d, Lymph nodes were analyzed for plasmacytoid dendritic cells (pDCs) and conventional CD11c⁺ DCs (cDC1). Only sGCs and NP vaccine groups demonstrated significantly increased pDC and cDC1 frequencies, respectively, relative to controls. e, Dots represent the distribution of individual serum samples at each dilution. Both immunogens elicited robust neutralizing activity at low serum dilutions (1:100–1:200). At higher dilutions (1:1600–1:6400), sera from mice immunized with MLD-GP38Δglyc exhibited significantly greater neutralization than the wild-type MLD-GP38 group, indicating that removal of GP38 glycans enhances the potency and/or durability of the neutralizing antibody response. Negative control sera (blue) showed minimal inhibition across all dilutions. f, ELISA revealed that 3 out of 6 mice in the NPmut group were positive, while no NP-vaccinated mice showed detectable antibody. Both sGCs and sGCs (GP38Δglyc) groups exhibited significantly higher antibody responses than negative controls, with no differences between these two groups. g and h, The immunization/grouping scheme in IS C57BL/6 mice. i, Weight, clinical score and survival of C57BL/6J mice vaccinated with CCHFV based mRNAs 35 days prior to challenge and provided a boost dose at 21 days prior to challenge (n = 10 per group). On the day of challenge, mice were transiently immunosuppressed with anti-mouse IFNAR-1 mAb IP and subsequently inoculated with CCHFV strain IbAr10200 SC. Weights depicted as percent change from baseline at D0. Clinical scores are shown as individual daily scores (0–10; increasing intensity of red indicates higher scores, and gray boxes denote end of monitoring due to euthanasia or reaching a lethal endpoint; top) or as mean scores for each experimental group (bottom).

    Journal: bioRxiv

    Article Title: A modular mRNA–LNP vaccine platform enables integrated RNA, lipid and antigen design to protect against CCHFV

    doi: 10.64898/2026.01.17.699915

    Figure Lengend Snippet: a, Female C57BL/6J mice were immunized intramuscularly with Cleancap M6 mRNA–LNP formulations encoding nucleocapsid (NP), mutant nucleocapsid (NPmut), sGCs, or sGCs (GP38Δglyc). Blood, spleens, and lymph nodes were collected on day 35 for downstream analyses, including ELISA, dendritic cell profiling, and ELISPOT assays. b, Splenocytes were stimulated for 24 hours with 10 µg/mL of nucleocapsid or GP38 proteins and analyzed by ELISPOT for IFN-γ and IL-4 secretion. NP and NPmut groups induced significantly higher IFN-γ responses compared with sGCs, sGCs (GP38Δglyc), and negative control, whereas sGCs and sGCs (GP38Δglyc) showed no significant IFN-γ response. None of the vaccine groups elicited significant IL-4 production. c, Splenocytes were stimulated ex vivo for 24 hours with 10 µg/mL of nucleocapsid or GP38 proteins and analyzed for intracellular cytokines IFN-γ, IL-2, and TNF-α in CD8⁺ and CD4⁺ T cells. All vaccine groups elicited robust CD4⁺ and CD8⁺ T cell responses compared with negative controls, except for sGCs (GP38Δglyc). NP vaccination induced significantly higher cytokine production in CD8⁺ T cells relative to control, whereas sGCs (GP38Δglyc) uniquely enhanced IL-2 and TNF-α in CD4⁺ T cells. No significant differences were observed among vaccine groups. d, Lymph nodes were analyzed for plasmacytoid dendritic cells (pDCs) and conventional CD11c⁺ DCs (cDC1). Only sGCs and NP vaccine groups demonstrated significantly increased pDC and cDC1 frequencies, respectively, relative to controls. e, Dots represent the distribution of individual serum samples at each dilution. Both immunogens elicited robust neutralizing activity at low serum dilutions (1:100–1:200). At higher dilutions (1:1600–1:6400), sera from mice immunized with MLD-GP38Δglyc exhibited significantly greater neutralization than the wild-type MLD-GP38 group, indicating that removal of GP38 glycans enhances the potency and/or durability of the neutralizing antibody response. Negative control sera (blue) showed minimal inhibition across all dilutions. f, ELISA revealed that 3 out of 6 mice in the NPmut group were positive, while no NP-vaccinated mice showed detectable antibody. Both sGCs and sGCs (GP38Δglyc) groups exhibited significantly higher antibody responses than negative controls, with no differences between these two groups. g and h, The immunization/grouping scheme in IS C57BL/6 mice. i, Weight, clinical score and survival of C57BL/6J mice vaccinated with CCHFV based mRNAs 35 days prior to challenge and provided a boost dose at 21 days prior to challenge (n = 10 per group). On the day of challenge, mice were transiently immunosuppressed with anti-mouse IFNAR-1 mAb IP and subsequently inoculated with CCHFV strain IbAr10200 SC. Weights depicted as percent change from baseline at D0. Clinical scores are shown as individual daily scores (0–10; increasing intensity of red indicates higher scores, and gray boxes denote end of monitoring due to euthanasia or reaching a lethal endpoint; top) or as mean scores for each experimental group (bottom).

    Article Snippet: Plates were washed once with 0.1% Tween-20 in PBS and blocked with 200 μL ChonBlock ELISA Buffer (Chondrex, Cat #9068) for 2 hours at room temperature.

    Techniques: Mutagenesis, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot, Negative Control, Ex Vivo, Control, Activity Assay, Neutralization, Inhibition